Certara

Yahoo Finance • 26 days ago

Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster

RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the availability of Pinnacle 21 Enterprise Plus. The solution enables clinical and statistical programmers to... Full story

Yahoo Finance • 27 days ago

Cerrado Gold Receives US$8.75M Payment from Hochschild

US$8.75m received from Hochschild Mining Plc. (“Hochschild”) as a prepayment of the US$10m obligation due July 2026Funds strengthen balance sheet, support acceleration of growth initiatives TORONTO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ce... Full story

Yahoo Finance • 28 days ago

Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: Baird Glob... Full story

Yahoo Finance • last month

Biosimulation Market to Attain USD 18.97 Billion by 2034, Rising at 16.9% CAGR

Ottawa, Aug. 18, 2025 (GLOBE NEWSWIRE) -- The global biosimulation market was valued at USD 3.97 billion in 2024 and is projected to reach approximately USD 18.97 billion by 2034, expanding at a CAGR of 16.9%, according to a study publis... Full story

Yahoo Finance • 2 months ago

Plant Biotechnology Company Evaluation Report 2025 | Bayer, Syngenta, and BASF Lead with Advanced Crop Protection, Seeds, and Sustainable Farming Solutions

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Plant Biotechnology - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering. The Plant Biotechnology Companies Quadrant is a comprehensive industry... Full story

Yahoo Finance • 2 months ago

Certara’s SWOT analysis: biosimulation firm’s stock faces growth hurdles

Certara, Inc. (NASDAQ:CERT), a leading provider of biosimulation software and technology services for drug discovery and development, has been navigating a complex market landscape in 2025. Trading at $11.20, with a market capitalization o... Full story

Yahoo Finance • 2 months ago

Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns

Investing.com - Leerink Partners has reduced its price target on Certara Inc . (NASDAQ:CERT) to $11.50 from $13.00 while maintaining an Outperform rating on the stock. The company’s shares currently trade at $11.13, with analyst targets r... Full story

Yahoo Finance • 2 months ago

Certara signals full year 8–10% revenue growth outlook as AI and QSP momentum builds

Earnings Call Insights: Certara, Inc. (CERT) Q2 2025 MANAGEMENT VIEW * William F. Feehery, CEO, stated that "Certara's second quarter performance reflected continued strength across the organization as we achieved results that were con... Full story

Yahoo Finance • 2 months ago

Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform

RADNOR, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of Christopher Bouton, Ph.D., as Chief Technology Officer. In this role, Bou... Full story

Yahoo Finance • 3 months ago

Simulations Plus Sees Weaker Demand Persist, Outlook Softens

Simulations Plus Inc. (NASDAQ:SLP) shares declined on Tuesday following the release of its third-quarter 2025 earnings report. The company reported sales of $20.4 million, representing a 10% year-over-year increase, but this fell short of... Full story

Yahoo Finance • 3 months ago

Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025

RADNOR, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2025 after the market close... Full story

Yahoo Finance • 3 months ago

Certara Announces Expansion of Clinical Technology Collaboration with Merck

Certara Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in mode... Full story

Yahoo Finance • 3 months ago

Certara stock rating initiated at Equalweight by Morgan Stanley

Investing.com - Morgan Stanley has initiated coverage on Certara Inc . (NASDAQ:CERT) with an Equalweight rating and a $16.00 price target. According to InvestingPro data, the company currently has a market capitalization of $1.86 billion,... Full story

Yahoo Finance • 3 months ago

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Key Points The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and... Full story

Yahoo Finance • 3 months ago

JMP analyst maintains Simulations Plus stock rating amid forecast cuts

JMP Securities maintained its Market Perform rating on Simulations Plus (NASDAQ:SLP) on Wednesday. The firm significantly reduced its financial forecasts for the pharmaceutical software company, citing near-term macroeconomic uncertainty... Full story

Yahoo Finance • 4 months ago

Is AI changing FDA-biopharma dynamics?

Investing.com -- Artificial intelligence is beginning to reshape how drug companies interact with the Food and Drug Administration, though most changes so far have been limited. According to analysts at BofA Securities, key steps in the d... Full story

Yahoo Finance • 4 months ago

Add Up The Pieces: VONE Could Be Worth $310

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 5 months ago

Certara Reports First Quarter 2025 Financial Results

RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: R... Full story

Yahoo Finance • 6 months ago

Why Certara Inc. (CERT) Skyrocketed On Monday?

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Certara Inc. (NASDAQ:CERT) stands against other biotech stocks that dominate Monday’s top gainers. The... Full story

Yahoo Finance • 6 months ago

Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing

RADNOR, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of its Non-Animal Navigator™ solution designed to help biopharmaceutical compani... Full story